Previous 10 | Next 10 |
Image source: The Motley Fool. Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) Q1 2020 Earnings Call May 12, 2020 , 8:30 a.m. ET Operator Continue reading
Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2020 Earnings Conference Call May 12, 2020 8:30 A.M. ET Company Participants Alicia Grande - Chief Financial Officer Patrick McEnany - Chairman and Chief Executive Officer Dan Brennan - Chief Commercial Officer Steven Miller - Chief Oper...
Genfit SA (NASDAQ: GNFT ) -67% after elafibranor flunks NASH study. More news on: Genfit SA, California Resources Corporation, Rand Capital, Stocks on the move, , Read more ...
Catalyst Pharmaceuticals (NASDAQ: CPRX ): Q1 Non-GAAP EPS of $0.12; GAAP EPS of $0.10 beats by $0.01 . Revenue of $29.1M (+133.7% Y/Y) misses by $2.36M . Shares -5% . Press Release More news on: Catalyst Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news...
Firdapse® Q1 2020 Net Revenues of $29.1 Million First Quarter 2020 GAAP Net Income of $10.4 Million Catalyst Withdraws Previous 2020 Revenue Guidance Due to COVID-19 Uncertainties Catalyst to Host Quarterly Conference Call at 8:30 AM ET Tomorrow CORAL GABLES, Fla., May 1...
CORAL GABLES, Fla., May 04, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurologica...
Like many biotech stocks , Catalyst Pharmaceuticals (NASDAQ: CPRX) has quickly rebounded from the low point it reached during the first quarter's pandemic-driven market plunge. The stock is up about 31% year-to-date, outperforming both the Virtus LifeSci Biotech Products ETF (up...
Are These Penny Stocks On Robinhood A Buy Or Sell Right Now? While the Robinhood app has run into its share of troubles, it hasn’t stopped users from trading penny stocks. Even amid the Robinhood shut down, people are still using the app for quick, on the fly trading. Whether or not you...
Catalyst Pharmaceuticals (NASDAQ: CPRX ) provides an update on impacts of COVID-19 on its business operations. More news on: Catalyst Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
Safety of personnel, patients and healthcare providers remains our top priority Drug supply remains well-stocked with patients having access to uninterrupted supply of Firdapse® (amifampridine) 10mg Catalyst partners with First Responders Children’s Fo...
News, Short Squeeze, Breakout and More Instantly...
Catalyst Pharmaceuticals Inc. Company Name:
CPRX Stock Symbol:
NASDAQ Market:
Catalyst Pharmaceuticals Inc. Website:
CORAL GABLES, Fla., July 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-...
2024-06-20 17:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-03 11:30:04 ET H.C. Wainwright analyst issues UNDERPERFORM recommendation for CPRX on June 3, 2024 09:00AM ET. The previous analyst recommendation was Underperform. CPRX was trading at $16.38 at issue of the analyst recommendation. The overall analyst consensus :...